Meeting of the Advisory Committee on Blood Safety and Availability, 73006 [E5-7084]
Download as PDF
<![CDATA[
73006
Federal Register / Vol. 70, No. 235 / Thursday, December 8, 2005 / Notices
1. First Federal Bancorp, Columbia,
Mississippi; to become a bank holding
company upon the conversion of its
wholly-owned thrift subsidiary, First
Federal Bank for Savings, Columbia,
Mississippi, to a state nonmember bank,
to be known as First Southern Bank,
Columbia, Mississippi.
Board of Governors of the Federal Reserve
System, December 5, 2005.
Robert deV. Frierson,
Deputy Secretary of the Board.
[FR Doc. E5–7060 Filed 12–7–05; 8:45 am]
BILLING CODE 6210–01–S
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Meeting of the Advisory Committee on
Blood Safety and Availability
Department of Health and
Human Services, Office of the Secretary.
ACTION: Notice.
AGENCY:
As stipulated by the Federal
Advisory Committee Act, the U.S.
Department of Health and Human
Services is hereby giving notice that the
Advisory Committee on Blood Safety
and Availability (ACBSA) will hold a
meeting. The meeting will be open to
the public.
DATES: The meeting will take place
Thursday, January 5, 2006 and Friday,
January 6, 2006 from 9 a.m. to 5 p.m.
ADDRESSES: Marriott Crystal Gateway,
1700 Jeff Davis Highway, Arlington, VA
22202.
FOR FURTHER INFORMATION CONTACT: Jerry
A. Holmberg, PhD, Executive Secretary,
Advisory Committee on Blood Safety
and Availability, Office of Public Health
and Science, Department of Health and
Human Services, 1101 Wootton
Parkway, Room 250, Rockville, MD
20852, (240) 453–8809, FAX (240) 453–
8456, e-mail
jholmberg@osophs.dhhs.gov.
SUPPLEMENTARY INFORMATION: The
ACBSA will meet to review progress
and solicit additional input regarding
numerous recommendations made
during the past year. Additionally, the
Committee will discuss strategies for
vigilant detection and management of
emerging or re-emerging infectious and
non-infectious events of transfusion
since it is a necessary first step toward
the goal of reducing the risk of
transfusion-transmitted diseases as well
as disease transmission through other
vital products such as bone marrow,
SUMMARY:
VerDate Aug<31>2005
16:29 Dec 07, 2005
Jkt 208001
progenitor cells, tissues, and organs.
The Committee will also be asked to
review current literature and hear
subject matter experts on the H5NI
avian flu virus and provide
recommendations for preparations
which should be considered for the
nation’s blood supply if a pandemic
influenza or similar pandemic event
occurs. Recommendations on the impact
of a pandemic on the availability of
blood, organs, and other tissue will be
requested.
Public comment will be solicited at
the meeting and will be limited to five
minutes per speaker. Anyone planning
to comment is encouraged to contact the
Executive Secretary at his/her earliest
convenience. Those who wish to have
printed material distributed to Advisory
Committee members should submit
thirty (30) copies to the Executive
Secretary prior to close of business
January 3, 2006. Likewise, those who
wish to utilize electronic data projection
to the Committee must submit their
materials to the Executive Secretary
prior to close of business January 3,
2006.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on
Blood Safety and Availability.
[FR Doc. E5–7084 Filed 12–7–05; 8:45 am]
BILLING CODE 4150–41–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Centers for Disease Control and
Prevention
[60 Day–06–0009]
Proposed Data Collections Submitted
for Public Comment and
Recommendations
In compliance with the requirement
of Section 3506(c)(2)(A) of the
Paperwork Reduction Act of 1995 for
opportunity for public comment on
proposed data collection projects, the
Centers for Disease Control and
Prevention (CDC) will publish periodic
summaries of proposed projects. To
request more information on the
proposed projects or to obtain a copy of
the data collection plans and
instruments, call 404–639–4766 and
send comments to Seleda Perryman,
CDC Assistant Reports Clearance
Officer, 1600 Clifton Road, MS–D74,
Atlanta, GA 30333 or send an e-mail to
omb@cdc.gov.
PO 00000
Frm 00030
Fmt 4703
Sfmt 4703
Comments are invited on: (a) Whether
the proposed collection of information
is necessary for the proper performance
of the functions of the agency, including
whether the information shall have
practical utility; (b) the accuracy of the
agency’s estimate of the burden of the
proposed collection of information; (c)
ways to enhance the quality, utility, and
clarity of the information to be
collected; and (d) ways to minimize the
burden of the collection of information
on respondents, including through the
use of automated collection techniques
or other forms of information
technology. Written comments should
be received within 60 days of this
notice.
Proposed Project
National Disease Surveillance
Program—I. Case Reports—Revision—
(NCID), Centers for Disease Control and
Prevention (CDC).
Background and Brief Description
Formal surveillance of 18 separate
reportable diseases has been ongoing to
meet the public demand and scientific
interest in accurate, consistent,
epidemiologic data. These ongoing
disease reports include: Active Bacterial
Core Surveillance (ABCs), CreutzfeldtJakob Disease (CJD), Cyclospora,
Dengue, Hantavirus, Idiopathic CD4+Tlymphocytopenia, Kawasaki Syndrome,
Legionellosis, Lyme disease, Malaria,
Plague, Q Fever, Reye Syndrome, Tickborne Rickettsial Disease, Trichinosis,
Tularemia, Typhoid Fever, and Viral
Hepatitis. Tularemia is a new addition
to this submission. Case report forms
from state and territorial health
departments enable CDC to collect
demographic, clinical, and laboratory
characteristics of cases of these diseases.
This information is used to direct
epidemiologic investigations, identify
and monitor trends in reemerging
infectious diseases or emerging modes
of transmission, to search for possible
causes or sources of the diseases, and
develop guidelines for prevention and
treatment. The data collected will also
be used to recommend target areas most
in need of vaccinations for selected
diseases and to determine development
of drug resistance.
Because of the distinct nature of each
of the diseases, the number of cases
reported annually is different for each.
There is no cost to respondents other
than their time.
E:\FR\FM\08DEN1.SGM
08DEN1
]]>Agencies
[Federal Register Volume 70, Number 235 (Thursday, December 8, 2005)]
[Notices]
[Page 73006]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E5-7084]
=======================================================================
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Meeting of the Advisory Committee on Blood Safety and
Availability
AGENCY: Department of Health and Human Services, Office of the
Secretary.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: As stipulated by the Federal Advisory Committee Act, the U.S.
Department of Health and Human Services is hereby giving notice that
the Advisory Committee on Blood Safety and Availability (ACBSA) will
hold a meeting. The meeting will be open to the public.
DATES: The meeting will take place Thursday, January 5, 2006 and
Friday, January 6, 2006 from 9 a.m. to 5 p.m.
ADDRESSES: Marriott Crystal Gateway, 1700 Jeff Davis Highway,
Arlington, VA 22202.
FOR FURTHER INFORMATION CONTACT: Jerry A. Holmberg, PhD, Executive
Secretary, Advisory Committee on Blood Safety and Availability, Office
of Public Health and Science, Department of Health and Human Services,
1101 Wootton Parkway, Room 250, Rockville, MD 20852, (240) 453-8809,
FAX (240) 453-8456, e-mail jholmberg@osophs.dhhs.gov.
SUPPLEMENTARY INFORMATION: The ACBSA will meet to review progress and
solicit additional input regarding numerous recommendations made during
the past year. Additionally, the Committee will discuss strategies for
vigilant detection and management of emerging or re-emerging infectious
and non-infectious events of transfusion since it is a necessary first
step toward the goal of reducing the risk of transfusion-transmitted
diseases as well as disease transmission through other vital products
such as bone marrow, progenitor cells, tissues, and organs. The
Committee will also be asked to review current literature and hear
subject matter experts on the H5NI avian flu virus and provide
recommendations for preparations which should be considered for the
nation's blood supply if a pandemic influenza or similar pandemic event
occurs. Recommendations on the impact of a pandemic on the availability
of blood, organs, and other tissue will be requested.
Public comment will be solicited at the meeting and will be limited
to five minutes per speaker. Anyone planning to comment is encouraged
to contact the Executive Secretary at his/her earliest convenience.
Those who wish to have printed material distributed to Advisory
Committee members should submit thirty (30) copies to the Executive
Secretary prior to close of business January 3, 2006. Likewise, those
who wish to utilize electronic data projection to the Committee must
submit their materials to the Executive Secretary prior to close of
business January 3, 2006.
Jerry A. Holmberg,
Executive Secretary, Advisory Committee on Blood Safety and
Availability.
[FR Doc. E5-7084 Filed 12-7-05; 8:45 am]
BILLING CODE 4150-41-P
